Becton, Dickinson and Company BDX · NYSE
$191.55 -1.14% (-$2.21)
Summary
47 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 42 years in a row.
- Out of every 100 USD of revenue, 13 USD is left as free cash.
What to watch
- You pay 55.4 USD for 1 USD of yearly profit, a lot for its sector.
- Repaying its net debt would take 4.1 years of operating profit.
- It pays out more in dividends than it earns: 115% of profit.
- Analysts expect revenue to fall by 12% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 55.4 USD for 1 USD of yearly profit. Over the last five years it was 30.3 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.3% a year over 5 years. Over the last 3 years it grew by 5.0% a year. For the next fiscal year analysts expect revenue to fall by 12%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 54 USD
- Research and development 5.5 USD
- Sales and administration 31 USD
- Taxes and other 5.3 USD
- Net profit 4.5 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.2 USD
Out of every 100 USD of revenue, 4.5 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.08%
- Paid out of profit
- 115%
- Raised in a row
- 42 years
You receive $3.98 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 16
- Hold 17
- Sell 1
Today's price within the analysts' price targets
The average target of $186.88 is 2.4% below today's price. 47% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Medical 52%
- Interventional 24%
- Life Sciences 24%
By region
- UNITED STATES 59%
- Europe 22%
- Asia 14%
- Others Country 5.6%
Medical brings in 52% of revenue. Interventional grew fastest, by 5.3% a year.
Segments in detail